Related Experiment Videos
Guidelines and methodological reviews concerning drug abuse liability assessment
Robert L Balster1, George E Bigelow
1Department of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298-0310, USA. balster@hsc.vcu.edu
Drug and Alcohol Dependence
|May 22, 2003
Summary
Assessing drug abuse liability is crucial for regulatory control and preventing misuse. Current guidelines need updates to incorporate scientific advances and address novel CNS-active medications effectively.
Area of Science:
- Pharmacology
- Drug Policy
- Neuroscience
Background:
- Regulatory control of drugs with abuse liability is key to preventing nonmedical use.
- Effective control necessitates scientific assessment of a drug's abuse liability.
- Existing methods rely on animal/human testing, clinical trials, and real-world data.
Purpose of the Study:
- Review proposed recommendations and guidelines for abuse liability assessment.
- Focus on drugs with medical usefulness, including traditional and novel CNS-active compounds.
- Identify areas for critical thinking and new guideline development.
Main Methods:
- Literature review of scientific assessments for drug abuse liability.
- Analysis of historical and current approaches to abuse liability evaluation.
- Discussion of consensus on assessing traditional drug classes (opiates, stimulants, etc.).
Main Results:
- Substantial consensus exists for assessing traditional drug classes.
- Novel CNS-active medications present challenges for existing assessment frameworks.
- Advances in abuse liability science require incorporation into future guidelines.
Conclusions:
- Existing guidelines for abuse liability assessment remain valuable but require updates.
- New guidelines are needed to address novel CNS-active medications.
- Guidance is essential for developers to balance therapeutic benefit with abuse risk.